Pfizer Inc. (NYSE:PFE) is among the 12 Best Ethical Companies to Invest in 2025. On July 24, 2025, Pfizer Inc. (NYSE:PFE) ...

Pfizer agreed to an upfront payment of US$1.25 billion, US$150 million for mainland rights and a US$100 million equity ...

As part of the agreement, which was signed in May 2025, 3SBio will receive $1.25bn, along with a $100m equity investment from ...

Moderna has scrapped plans to build an mRNA plant in Japan. Otsuka and Lundbeck's proposal for Rexulti as part of a PTSD ...

Northeastern Chinese company 3SBio to receive $1.25B, in addition to $100M equity investment, $150M for exclusive rights in ...

HONG KONG, Aug. 24, 2023 /PRNewswire/ -- Chinese leading biopharmaceutical company 3SBio (01530.HK) today released its 2023 interim results. Revenue in the first half of 2023 reached approximately ...

3SBio has good financial health. As of 2020, total debt was CNY 3 billion, net debt was minus CNY 218 million, and net debt to equity was negative 2%. The company generates approximately CNY 1 ...

Pfizer secrued exclusive global rights to 3SBio's cancer treatment candidate. It is a a licensing deal that could be worth $6.05 billion.

Written by Zacks Equity Research for Zacks -> Pharmaceutical giant Pfizer Inc. PFE has signed a significant licensing agreement with China's 3SBio Inc. for an experimental cancer drug, SSGJ-707.